Rheumatoid Arthritis and Risk of Parkinson Disease in Korea.

Importance Although it has been postulated that chronic inflammation caused by rheumatoid arthritis (RA) contributes to the development of Parkinson disease (PD), the association between these 2 conditions has yet to be determined. Objective To evaluate the association between RA and subsequent PD risk. Design, Setting, and Participants This retrospective cohort study used the Korean National Health Insurance Service database to collect population-based, nationally representative data on patients with RA enrolled from 2010 to 2017 and followed up until 2019 (median follow-up, 4.3 [IQR, 2.6-6.4] years after a 1-year lag). A total of 119 788 patients who were first diagnosed with RA (83 064 with seropositive RA [SPRA], 36 724 with seronegative RA [SNRA]) were identified during the study period and included those who underwent a national health checkup within 2 years before the RA diagnosis date (64 457 patients). After applying exclusion criteria (eg, age <40 years, other rheumatic diseases, previous PD), 54 680 patients (39 010 with SPRA, 15 670 with SNRA) were included. A 1:5 age- and sex-matched control group of patients without RA was also included for a total control population of 273 400. Exposures Rheumatoid arthritis as defined using International Classification of Diseases, Tenth Revision codes M05 for SPRA and M06 (except M06.1 and M06.4) for SNRA; prescription of any disease-modifying antirheumatic drug; and enrollment in the Korean Rare and Intractable Diseases program. Main Outcomes and Measures The main outcome was newly diagnosed PD. Data were analyzed from May 10 through August 1, 2022, using Cox proportional hazards regression analyses. Results From the 328 080 individuals analyzed (mean [SD] age, 58.6 [10.1] years; 74.9% female and 25.1% male), 1093 developed PD (803 controls and 290 with RA). Participants with RA had a 1.74-fold higher risk of PD vs controls (95% CI, 1.52-1.99). An increased risk of PD was found in patients with SPRA (adjusted hazard ratio [aHR], 1.95; 95% CI, 1.68-2.26) but not in patients with SNRA (aHR, 1.20; 95% CI, 0.91-1.57). Compared with the SNRA group, those with SPRA had a higher risk of PD (aHR, 1.61; 95% CI, 1.20-2.16). There was no significant interaction between covariates on risk of PD. Conclusions and Relevance In this study, RA was associated with an increased risk of PD, and seropositivity of RA conferred an augmented risk of PD. The findings suggest that physicians should be aware of the elevated risk of PD in patients with RA and promptly refer patients to a neurologist at onset of early motor symptoms of PD without synovitis.

[1]  B. Cho,et al.  National General Health Screening Program in Korea: history, current status, and future direction: A scoping review , 2022, Precision and Future Medicine.

[2]  D. Shin,et al.  Sex differences in the association between nonalcoholic fatty liver disease and Parkinson's disease. , 2021, Parkinsonism & related disorders.

[3]  M. Mielke,et al.  POS0309 SEROPOSITIVITY INCREASES RISK OF INCIDENT DEMENTIA IN INDIVIDUALS WITH RHEUMATOID ARTHRITIS: A POPULATION-BASED COHORT STUDY , 2021, Annals of the Rheumatic Diseases.

[4]  L. Brundin,et al.  Decreased Risk of Parkinson’s Disease After Rheumatoid Arthritis Diagnosis: A Nested Case-Control Study with Matched Cases and Controls , 2021, Journal of Parkinson's disease.

[5]  D. Shin,et al.  Female reproductive factors and the risk of Parkinson’s disease: a nationwide cohort study , 2020, European Journal of Epidemiology.

[6]  S. Rhee,et al.  Association Between Glycemic Status and the Risk of Parkinson Disease: A Nationwide Population-Based Study , 2020, Diabetes Care.

[7]  J. Jankovic,et al.  Parkinson disease and the immune system — associations, mechanisms and therapeutics , 2020, Nature Reviews Neurology.

[8]  S. Rhee,et al.  Body Mass Index, Diabetes, and the Risk of Parkinson's Disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[9]  Kyungdo Han,et al.  Trends in the incidence and prevalence of Parkinson’s disease in Korea: a nationwide, population-based study , 2019, BMC Geriatrics.

[10]  K. Choi,et al.  Chronic renal dysfunction, proteinuria, and risk of Parkinson's disease in the elderly , 2019, Movement disorders : official journal of the Movement Disorder Society.

[11]  D. Shin,et al.  Association of statin use with Parkinson's disease: Dose–response relationship , 2019, Movement disorders : official journal of the Movement Disorder Society.

[12]  M. Dubinsky,et al.  Anti–Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease , 2018, JAMA neurology.

[13]  W. Poewe,et al.  Validation of the MDS clinical diagnostic criteria for Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[14]  Yu-Sheng Chang,et al.  Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan , 2018, Annals of medicine.

[15]  Nicholas W Wood,et al.  Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases , 2017, JAMA neurology.

[16]  N. Chen,et al.  Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation. , 2017, Toxicology letters.

[17]  Hee-Jin Kang,et al.  Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea , 2016, International journal of epidemiology.

[18]  Y. Chou,et al.  Reduced Risk of Parkinson Disease in Patients With Rheumatoid Arthritis: A Nationwide Population-Based Study. , 2016, Mayo Clinic proceedings.

[19]  V. Manganelli,et al.  Autophagy generates citrullinated peptides in human synoviocytes: a possible trigger for anti-citrullinated peptide antibodies. , 2016, Rheumatology.

[20]  Lawrence H. Kushi,et al.  Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals. , 2016, JAMA cardiology.

[21]  E. Keystone,et al.  Prognosis of Seronegative Patients in a Large Prospective Cohort of Patients with Early Inflammatory Arthritis , 2014, The Journal of Rheumatology.

[22]  S. Bae,et al.  Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database , 2013, Rheumatology International.

[23]  R. Nixon,et al.  The role of autophagy in neurodegenerative disease , 2013, Nature Medicine.

[24]  F. Pitossi,et al.  Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson’s Disease? , 2013, Frontiers in Cellular Neuroscience.

[25]  J. Sundquist,et al.  Subsequent Risks of Parkinson Disease in Patients with Autoimmune and Related Disorders: A Nationwide Epidemiological Study from Sweden , 2011, Neurodegenerative Diseases.

[26]  E. Unanue,et al.  Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells , 2011, The Journal of experimental medicine.

[27]  Georg Schett,et al.  The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.

[28]  I. Ferrer,et al.  Chaperone-mediated autophagy markers in Parkinson disease brains. , 2010, Archives of neurology.

[29]  M. Vila,et al.  Pathogenic Lysosomal Depletion in Parkinson's Disease , 2010, The Journal of Neuroscience.

[30]  A. Barton,et al.  Benefit of early treatment in inflammatory polyarthritis patients with anti–cyclic citrullinated peptide antibodies versus those without antibodies , 2010, Arthritis care & research.

[31]  M. Farrer,et al.  LRRK2 and Parkinson disease. , 2010, Archives of neurology.

[32]  S. Rexhepi,et al.  Extra-articular manifestations of seronegative and seropositive rheumatoid arthritis. , 2010, Bosnian journal of basic medical sciences.

[33]  J. Olsen,et al.  Autoimmune disease and risk for Parkinson disease , 2009, Neurology.

[34]  A. Ascherio,et al.  Family history of melanoma and Parkinson disease risk , 2009, Neurology.

[35]  F. Gage,et al.  A Nurr1/CoREST Pathway in Microglia and Astrocytes Protects Dopaminergic Neurons from Inflammation-Induced Death , 2009, Cell.

[36]  D. Sugiyama,et al.  Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies , 2009, Annals of the rheumatic diseases.

[37]  M. Tansey,et al.  Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention , 2007, Experimental Neurology.

[38]  Honglei Chen,et al.  Peripheral inflammatory biomarkers and risk of Parkinson's disease. , 2007, American journal of epidemiology.

[39]  C. Ferrari,et al.  Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra , 2006, Neurobiology of Disease.

[40]  B. Botterman,et al.  Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease , 2006, The Journal of Neuroscience.

[41]  Miguel A Hernán,et al.  A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.

[42]  R. Dobbs,et al.  Association of circulating TNF‐α and IL‐6 with ageing and parkinsonism , 1999 .

[43]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[44]  E. Guallar,et al.  Association of cardiovascular health screening with mortality, clinical outcomes, and health care cost: a nationwide cohort study. , 2015, Preventive medicine.

[45]  R. Feldman,et al.  Environmental Toxins and Parkinson's Disease , 2005 .

[46]  R. Maini,et al.  The Role of Cytokines in Rheumatoid Arthritis , 1996, Journal of the Royal College of Physicians of London.